De novo methylation of CpG islands is seen in many cancers, but the general rules governing this process are not known. By analyzing DNA from tumors, as well as normal tissues, and by utilizing a range of published data, we have identified a universal set of tumor targets, each with its own "coefficient" of methylation that is largely correlated with its inherent relative ability to recruit polycomb. This pattern is initially formed by a slow process of de novo methylation that occurs during aging and then undergoes expansion early in tumorigenesis where, we hypothesize, it may act as an inhibitor of development-associated gene activation.
INTRODUCTION
Many studies have begun to shed light on the normal genome-wide pattern of DNA methylation during development (1) (2) (3) . It is now clear that following erasure in the early embryo there is a wave of de novo methylation that occurs at about the time of implantation, generating a bimodal pattern in which most CpGs become methylated while CpG-island-like sequences are protected (4, 5) . This pattern is then maintained through cell divisions in the adult, and only a minority of these islands gets methylated in somatic cells during normal development (1, 3) .
It is well known that CpG islands get aberrantly hypermethylated in cancer (6) and from genome-wide analyses it is clear that a large number of islands are involved (7) (8) (9) . Nonetheless, in these studies genes are usually classified as being methylated or not methylated in the tumor as compared to the source tissue using an arbitrary threshold for DNA modification without taking into consideration the actual levels of methylation at individual CpG islands in different tissue types. For this reason, there is a need to analyze this data in a more holistic manner that better reflects this process in vivo.
Although it has been shown that a large percentage of tumor-methylated sequences are polycomb target genes (10) (11) (12) that may already be repressed in the parent cell type (13, 14) , little is known about the dynamics of this process during tumorigenesis. Based on a relatively small number of sequences, several studies noted that the pattern of DNA methylation in tumors may be similar to that associated with aging (15) , but the dynamic Author Manuscript Published OnlineFirst on January 22, 2014; DOI: 10.1158/0008-5472.CAN- genome-wide relationship between aging-related and cancer-related methylation has not been elucidated. Similarly, the rules that govern tissueof-origin specificity in cancer, as well as the impact of this modification on gene expression and tumor physiology, are not well understood.
We have attempted to take a closer look at genome-wide DNA methylation from a developmental perspective. By combining this with a re-analysis of previously published data from a variety of different tumor types, we have been able to derive general rules that characterize the origin and general behavior of DNA methylation in cancer biology. 
MATERIALS AND METHODS

Methylation analysis
Human DNA samples were purchased from Biochain or Bioserve (Supplementary Table S1 ). Human genomic DNA (10 μg) was sonicated to an average fragment size of 300-1000 bp, precipitated with 400 mM NaCl, 2 volumes of ethanol and 1 μl glycogen. 1.5 μg were set aside as the Input fraction. DNA was denatured and anti-5-methylcytidine monoclonal antibody (10 μl for 5 μg) (16, 17) was added and incubated on a rotator at 4°C overnight. 40 μl Dynabeads (Sheep anti-Mouse IgG) were prewashed with 0.1% BSA/PBS and added to the DNA. The DNA was then washed 3 times and Ab-bound DNA resuspended and extracted with proteinase K, phenolchloroform and ethanol precipitation. Purified DNA was checked for enrichment (Bound/Input) using Real time PCR on specific gene regions known to be methylated.
The Input and Bound DNAs were labeled and hybridized on human (244 K) CpG island microarrays or human DNA methylation microarrays (244 K) (Agilent Technologies) as described previously (3) . We used feature extraction software (Agilent) to obtain background-subtracted intensity values for the two fluorescence dyes on each individual array feature and for carrying out linear normalization and calculation of the log ratio (Cy5/Cy3). Data was analyzed as previously described (3) . Briefly, probe log ratio signals were transformed into Z-scores according to their Tm and an Island Methylation Score (IMS) was then calculated by averaging the island corresponding probes' Z-scores. We defined a set of "background" CpG islands by selecting 6 those with an IMS of less than 0.5 in all 10 fetal tissue samples (Brain, Liver, Skeletal Muscle and Colon, Supplementary Table S1 ). Microarray data is available at the Gene Expression Omnibus (GEO) repository under accession GSE38142.
Bisulfite Analysis
Bisulfite conversion of genomic DNA was carried out using the EZ DNA Methylation-Direct Kit (Zymo Research) according to the manufacturer's instructions. PCR primers were designed using Methyl Primer Express® Software v1.0 (Applied Biosystems). Barcodes and adaptors were added to the primers and deep-sequenced using the Ion Torrent (Life Technologies). 
RESULTS
Methylation patterns in cancer
The global bimodal methylation pattern of the human genome is established at the time of implantation and then maintained throughout development and adult life (18) . Thus, in order to objectively study de novo methylation in cancer and its relationship to aging, we first identified all of the unmethylated CpG islands formed in the embryo and then determined their modification patterns in normal tissues and tumors. This approach allowed us to obtain an overall picture of tumor methylation as opposed to other studies which generally focused on specific cancers and their tissues of origin.
We have adopted mDIP microarray technology to analyze the global methylation state of CpG islands (2, 3, 13) . This method has the advantage that it provides an excellent validated (3) measure of average methylation levels over each island. We first analyzed a variety of different fetal tissues (Supplementary Table S1 ) and identified over 13,000 CpG islands that have constitutively low Island Methylation Scores (IMS) of methylation (Materials and Methods) in all ten samples examined. In this way, we defined a background set of sequences that were originally set up as unmethylated at implantation. We then used mDIP to compile the levels of methylation for these same islands in individual colorectal cancers (CRC) and ordered them from the most down to the least modified sequences. As can be seen in To better visualize this phenomenon, we selected the top 1,524 CRC islands (IMS > 0.6) and mapped their methylation levels as they project onto other tumors using our own data for lung, as well as public data for breast (19) and pancreatic cancer. These distribution curves demonstrate that this same set of islands is modified in other tumors, as well. Furthermore, it appears that the set of highest methylation-ranked CpG islands in a wide range of other tumors is always found to be significantly enriched (P < 10 -300 ) with the same set of ~1,500 CRC islands ( Fig. 1B and Supplementary Table S2) , as determined by the minimal hypergeometric test (mHG) (20, 21) . These results suggest that there is a universal set of sequences commonly modified in many tumors.
Source of de novo methylation
Several studies have addressed the question of how DNA methylation arises during tumorigenesis (22) (23) (24) . To obtain some indication about the source of tumor-related methylation, we used the same CRC islands ( Fig. 1 ) and mapped their profile (IMS) in normal colon DNA from age-ranked samples.
Strikingly, these methylated islands form a well-defined population whose methylation levels in colon are significantly higher than the average set of constitutively unmethylated sequences (background islands) and increase as a function of aging ( Fig. 2 and Supplementary Fig. S1A ). It thus appears that these CpG islands are already specifically modified in normal colon tissue, and the same seems to be true for other cell types, as well. In contrast, no significant excess methylation was detected for ES cell DNA which represents the pattern present at implantation (Supplementary Fig. S2 ).
It should be noted that the overall levels of this excess DNA methylation are relatively low in normal tissues, and despite the recent identification of some age-dependent sequences (25) , it is unlikely that the full modification picture would have been detected. It is only because we specifically pinpointed the cancer-associated target population that we could distinguish this phenomenon. Nonetheless, analysis of age-related methylation from our data Table S2) , independent of the actual overall levels of excess methylation in each DNA sample (Fig. 3A ) using our own data as well as that from the literature, and this was confirmed by demonstrating that the rank variance across all samples is very low (Supplementary Fig. S4C ).
This same relationship is also observed when the Island Methylation Scores of each site are plotted as a function of their rank in normal colon (Fig. 3B) .
Finally, we generated a scatter plot for all background CpG islands comparing samples from CRC and other tumors ( Supplementary Fig. S4D ). These data clearly show that the patterns of methylation are very similar even though the overall intensity of modification is higher in the CRC samples. Taken together, these results suggest that every island has its own inherent methylation propensity independent of the source of DNA or the measurement platform. Based on ChIP data from ES cells, it has been suggested that the polycomb complex may play a role in recruiting DNA methylases to specific CpG islands in cancer (10) (11) (12) , but this relationship has never been tested by mapping polycomb sites in the actual tissue that gives rise to the tumor. We took advantage of H3K27me3 ChIP-Seq data for normal colon mucosa (29) , and plotted the degree of DNA methylation (IMS) at all CpG islands as a function of their polycomb-catalyzed H3K27me3 density (Fig. 4A) . Strikingly, we detected a monotonically increasing relationship between these two parameters, strongly suggesting that Polycomb components already present in the primary tissue may serve as a biochemical predictor for the amount of de novo DNA methylation ultimately seen in tumors. Indeed, abnormal methylation appears to take place mainly in the 35% of the genome that has above-normal background levels of H3K27me3, while CpG islands that lack this histone mark (< 3.5) appear to be free of DNA modification (Fig. 4A) .
Histone modification and de novo DNA methylation
Indeed, over 88% of the CRC islands are polycomb positive according to this criterion (P < 10 -300 , hypergeometric test).
Many studies have shown an inverse correlation between DNA methylation and H3K4me3 (2, 30) and it is thought that this histone modification may actually protect the underlying DNA from becoming methylated (31, 32) . To test whether this is also true for de novo methylation in cancer, we analyzed all H3K27me3-positive CpG islands in normal colon and plotted their CRC methylation levels as a function of H3K4me3 concentrations (Fig. 4B ). These data show that the presence of H3K4me3 has a marked negative effect on the degree of local de novo methylation in tumors. Indeed, at every level of 
H3K27me3, sites with high concentrations of H3K4me3 are less methylated than those with lower concentrations (Supplementary Fig. S5A ).
Using this data and employing machine learning methods (WEKA) (33), we devised a predictor for DNA methylation levels in cancer as a function of local histone modification density in the source tissue (Supplementary Methods), and then cross-validated this function in a separate test sample (Fig. 4C and Supplementary Fig. S5B ). This analysis indicates that the patterns of Despite previous studies showing a correlation between de novo methylation in cancer and the distribution of polycomb in ES cells (10, 12) , the histone modification profile in primary colon tissue is a much better predictor of abnormal methylation (Supplementary Fig. S5C ).
Tumor-specific methylation
While the overall pattern of DNA methylation appears to be universal, some de novo methylation may be tumor-type specific, as has been previously suggested (34, 35). To determine whether this tissue specificity can also be explained by the molecular rules governing cancer methylation, we selected CAN-13-3042 types. In colon, however, the concentration of H3K4me3 at these sites is much higher, on average, than what is seen at most CpG islands that undergo de novo methylation in colon cancer (Fig. 5A) . Similar results were obtained for tissue-specific de novo methylation in breast and liver tumors. This effect cannot be attributed to differences in levels of H3K27me3 at these sites (data not shown). These results suggest that tissue-specific differences are strongly correlated with local packaging of H3K4me3, in keeping with the principles derived by our predictor (Fig. 4) .
In addition to the large number of constitutively unmethylated background islands used in our studies, there are many CpG islands that undergo tissuespecific de novo methylation during normal development (1, 3) . Since these methyl footprints are unique to each individual cell type, we reasoned that all tumors originating from a particular tissue should bear these same distinctive marks, thus providing a type of barcode for identifying tumor origin. To test this idea, we compared DNA methylation patterns from colon tumors and hepatomas.
We identified approximately 20 CpG islands specifically methylated in normal colon, and all were found to be modified in colorectal cancer. In contrast, these CpG islands were unmethylated in hepatomas. Conversely, we identified a set of CpG islands methylated in normal liver and these continue to carry this mark in primary hepatomas (Fig. 5B) . Using this same strategy, we were also able to distinguish between lung and liver tumor samples ( Supplementary Fig. S6 ). While this form of lineage tracing is not necessarily Fig. 5B and Supplementary Fig. S6 ) shows that they retain these differential patterns, suggesting that this information can be used for identifying their tissue-of-origin in cases where it is unclear from the morphology alone. Fig. S5B ). Our data also show that the combined histone modification signature in the somatic tissues from which the tumors are derived, as opposed to ES cells, represents the most accurate indicator of DNA methylation, dispelling the previously suggested (10, 12) concept that tumor methylation is merely a reflection of stem-cell chromatin patterns (Supplementary Fig. S5C ).
Understanding the dynamics of age-dependent de novo methylation may also provide insight into the origins of tumor-associated modification patterns (36) .
Although the overall levels of methylation in normal tissue are much lower than those observed in tumors ( Supplementary Fig. S3 ), their modification target pattern is almost identical (Fig. 3B ). To generate a better picture for the distribution of DNA methylation in a tissue context, we carried out singlemolecule bisulfite sequencing of CpG islands using high-throughput IonTorrent technology (Fig. 6 and Supplementary Fig. S1A ). From this data, it is clear that cells in the normal colon have an unexpectedly wide distribution of methylation levels at individual CpG islands, with some molecules being completely methylated, while others show only minimal modification.
Considering that the methylation ranking rules in total DNA must also apply in 
Methylation of well-known tumor suppressor genes represents a key example of this proposed regulatory pathway but other genes that affect tumorassociated traits may also be involved (6, 43) . In keeping with this concept, removal of DNA methylation by treatment with 5azaC appears to bring about the reversion of cancer cell lines to a more normal phenotype (44) .
While this may represent one aspect of methylation, the extensive pattern of DNA modification observed in the tumors analyzed in this study strongly suggests that this modification process could have a more multi-faceted effect on tumorigenesis. Interestingly, over 90% of de novo methylated genes appear to be already repressed in normal tissue (13, 14) , and this has been confirmed in this study, as well (mHG P < 10 -55 , Supplementary Fig. S7A ).
This raises the intriguing possibility that DNA methylation may actually play a role in preventing the activation of target genes in the tumor (45) rather than repressing genes that were previously turned on in the normal tissue. This idea would also be consistent with the mechanistic strategy of de novo methylation as it occurs during normal development in vivo (46) .
One of the most striking features of abnormal methylation is that it targets many genes involved in development, morphogenesis, organogenesis or differentiation ( Supplementary Fig. S7B ). (14, 47) , the end result is that genes normally repressed by a relatively flexible mechanism directed by polycomb binding become stably and perhaps irreversibly silenced through modification of the underlying DNA itself (45) (Supplementary Fig. S7A ).
In the case of colon, tumors probably originate in proliferating cells of the crypt prior to their conversion to colonic epithelium (48) . It is likely that this epithelial differentiation involves activating a defined set of genes that are initially repressed in cells of the crypt (11, 49) . As we have demonstrated, Table S2 ). 
